Suppr超能文献

前列腺癌手术过度治疗的趋势

Trends in Surgical Overtreatment of Prostate Cancer.

作者信息

Monda Steven M, Demus Timothy, Jaime-Casas Salvador, Meah Sabir, Srivastava Arnav, Sarle Richard, Labardee Corinne, Ghani Khurshid R, Ginsburg Kevin M, Morgan Todd M, Borza Tudor

机构信息

Department of Urology, University of Michigan, Ann Arbor.

Department of Urology, Sparrow Health System, Lansing, Michigan.

出版信息

JAMA Oncol. 2025 Apr 28. doi: 10.1001/jamaoncol.2025.0963.

Abstract

IMPORTANCE

Overtreatment of prostate cancer is a public health concern that undermines prostate cancer screening efforts.

OBJECTIVE

To assess trends in pathologic grade on prostatectomy during the past 2 decades as a surrogate for overtreatment.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study examined the grade of prostate cancer on final pathology reports among patients undergoing prostatectomy between January 1, 2010, and September 1, 2024, in 2 parallel cohorts: Surveillance, Epidemiology, and End Results (SEER), a nationwide cancer registry, and Michigan Urological Surgery Improvement Collaborative (MUSIC), a statewide clinical registry. The presence of higher-risk features among patients who underwent grade group 1 prostatectomy during this period was also assessed.

EXPOSURES

The primary exposure of interest was year of radical prostatectomy.

MAIN OUTCOMES AND MEASURES

The primary outcome was the proportion of all prostatectomies that were pathologic grade group 1 (pGG1) on final pathology reports. The secondary outcome was the proportion of pGG1 prostatectomies with a higher-risk preoperative feature, assessed as a binary variable and including at least 1 of the following: more than 50% of biopsy cores positive, prostate-specific antigen of 10 ng/mL or higher, or grade group 2 on biopsy.

RESULTS

A total of 162 558 male patients in SEER (median [IQR] age, 63 [57-67] years) and 23 370 in MUSIC (median [IQR] age, 64 [59-69] years) underwent prostatectomy. The proportion of radical prostatectomies resulting in pGG1 on final pathology reports decreased from 32.4% (5852 of 18 071) to 7.8% (978 of 12 500) between 2010 and 2020 in SEER and from 20.7% (83 of 401) to 2.7% (32 of 1192) between 2012 and 2024 in MUSIC. A more recent prostatectomy was associated with a lower likelihood of a pGG1 prostatectomy while controlling for age and race within SEER (odds ratio [OR] per 5 years, 0.41; 95% CI, 0.40-0.42; P < .001) and MUSIC (OR per 5 years, 0.39; 95% CI, 0.36-0.43; P < .001). Within a subset analysis of those prostatectomies that were final pGG1, a more recent prostatectomy was associated with the presence of a higher-risk preoperative feature, including more than 50% of biopsy cores positive, prostate-specific antigen of 10 ng/mL or higher, and grade group 2 on prior biopsy within SEER (OR per 5 years, 1.60; 95% CI, 1.54-1.67; P < .001) and MUSIC (OR per 5 years, 1.60; 95% CI, 1.34-1.90; P < .001).

CONCLUSIONS AND RELEVANCE

This cohort study found that since 2010, the frequency of pGG1 prostatectomies markedly decreased, and those few that were performed were more likely to have a higher-risk feature. This reduction in the proportion of prostatectomies that are pGG1 likely reflects improved diagnostic pathways, adherence to active surveillance protocols for low-risk cases, and ongoing efforts at both the state and national levels to minimize unnecessary surgical interventions in patients diagnosed with clinically insignificant prostate cancer.

摘要

重要性

前列腺癌的过度治疗是一个公共卫生问题,会削弱前列腺癌筛查工作。

目的

评估过去20年前列腺切除术中病理分级的趋势,以此作为过度治疗的替代指标。

设计、设置和参与者:这项回顾性队列研究在两个平行队列中,检查了2010年1月1日至2024年9月1日期间接受前列腺切除术患者的最终病理报告中的前列腺癌分级:全国癌症登记处监测、流行病学和最终结果(SEER),以及全州临床登记处密歇根泌尿外科学改进协作组(MUSIC)。还评估了在此期间接受1级前列腺切除术患者中高风险特征的存在情况。

暴露因素

主要关注的暴露因素是根治性前列腺切除术的年份。

主要结局和测量指标

主要结局是最终病理报告中所有前列腺切除术为病理1级(pGG1)的比例。次要结局是pGG1前列腺切除术中具有高风险术前特征的比例,评估为二元变量,包括以下至少一项:超过50%的活检核心为阳性、前列腺特异性抗原为10 ng/mL或更高,或活检时为2级。

结果

SEER队列中共有162558名男性患者(年龄中位数[四分位间距],63[57 - 67]岁),MUSIC队列中有23370名(年龄中位数[四分位间距],64[59 - 69]岁)接受了前列腺切除术。在SEER中,2010年至2020年间,最终病理报告为pGG1的根治性前列腺切除术比例从32.4%(18071例中的5852例)降至7.8%(12500例中的978例);在MUSIC中,2012年至2024年间,该比例从20.7%(401例中的83例)降至2.7%(1192例中的32例)。在SEER(优势比[OR]每5年,0.41;95%置信区间,0.40 - 0.42;P <.001)和MUSIC(OR每5年,0.39;95%置信区间,0.36 - 0.43;P <.001)中,控制年龄和种族后,更近一次的前列腺切除术与pGG1前列腺切除术的可能性较低相关。在那些最终为pGG1的前列腺切除术亚组分析中,更近一次的前列腺切除术与高风险术前特征的存在相关,包括在SEER中超过50%的活检核心为阳性、前列腺特异性抗原为10 ng/mL或更高,以及先前活检时为2级(OR每5年,1.60;95%置信区间,1.54 - 1.67;P <.001)和MUSIC(OR每5年,1.60;95%置信区间,1.34 - 1.90;P <.001)。

结论和相关性

这项队列研究发现,自2010年以来,pGG1前列腺切除术的频率显著下降,而少数进行的此类手术更可能具有高风险特征。pGG1前列腺切除术比例的降低可能反映了诊断途径的改善、对低风险病例积极监测方案的依从性,以及州和国家层面为尽量减少对诊断为临床意义不显著的前列腺癌患者进行不必要的手术干预所做的持续努力。

相似文献

1
Trends in Surgical Overtreatment of Prostate Cancer.
JAMA Oncol. 2025 Apr 28. doi: 10.1001/jamaoncol.2025.0963.
2
Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.
Cochrane Database Syst Rev. 2017 Sep 12;9(9):CD009625. doi: 10.1002/14651858.CD009625.pub2.
3
Screening for prostate cancer.
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.
5
Cryotherapy for localised prostate cancer.
Cochrane Database Syst Rev. 2007 Jul 18(3):CD005010. doi: 10.1002/14651858.CD005010.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD006019. doi: 10.1002/14651858.CD006019.pub2.
9
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

本文引用的文献

1
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020.
JAMA. 2024 Dec 17;332(23):2033-2036. doi: 10.1001/jama.2024.20580.
2
Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era.
JAMA Intern Med. 2025 Jan 1;185(1):28-36. doi: 10.1001/jamainternmed.2024.5994.
3
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
N Engl J Med. 2024 Oct 10;391(14):1362-1364. doi: 10.1056/NEJMc2406108.
4
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
JAMA. 2024 Jun 25;331(24):2084-2093. doi: 10.1001/jama.2024.6695.
5
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
J Natl Compr Canc Netw. 2024 Apr;22(3):140-150. doi: 10.6004/jnccn.2024.0019.
7
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
N Engl J Med. 2023 Apr 27;388(17):1547-1558. doi: 10.1056/NEJMoa2214122. Epub 2023 Mar 11.
8
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
JAMA Netw Open. 2023 Mar 1;6(3):e231439. doi: 10.1001/jamanetworkopen.2023.1439.
10
The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide.
Eur Urol. 2023 Apr;83(4):307-310. doi: 10.1016/j.eururo.2022.05.028. Epub 2022 Jun 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验